Impact of the introduction of the pneumococcal vaccine on child morbidity and mortality in Ecuador
DOI:
https://doi.org/10.54753/rsh.v2i1.2679Keywords:
Pneumococcus, conjugate vaccine, infant morbidity, Ecuador, PCV10, PCV13Abstract
Invasive pneumococcal disease remains a major cause of childhood morbidity and mortality in developing countries. In Ecuador, the implementation of the 10-valent pneumococcal conjugate vaccine (PCV10) and the recent upgrade to PCV13 in 2025 represent historic milestones in child health care and protection. This article compiles evidence published between 2021 and 2025 on the impact of this vaccine on national health, morbidity and mortality, and cost-effectiveness in the national health system. The information collected shows a significant decrease in the frequency of pneumonia and preventable complications. However, ensuring its coverage in the country and monitoring for serotypes not covered by it remains a challenge for future generations. In conclusion, the transition to PCV13 represents a significant epidemiological change, and employing reinforcement strategies and equity in access are key to success in prevention and pediatric health promotion.References
[1] Ipiales LE. Neumonía bacteriana en niños en Ecuador: una mirada al impacto de las vacunas. Rev Infectol Pediatr. 2023;37(2):145-152.
[2] Jimbo-Sotomayor R, Sánchez M, Carrión J. Return on investment of 10-valent pneumococcal conjugate vaccine in Ecuador. Vaccine. 2022;40(15):2123-2130.
[3] Ministerio de Salud Pública (MSP). Actualización del esquema nacional de vacunación. MSP; 2025.
[4] Organización Panamericana de la Salud (OPS). Informe regional sobre vacunación neumocócica. OPS; 2025.
[5] Pan American Health Organization (PAHO). Pneumococcal conjugate vaccine impact in Latin America. Washington DC: PAHO; 2018.
[6] Sotomayor R, Sánchez M, Carrión J. Impacto de la vacuna neumocócica conjugada en hospitalizaciones y mortalidad por neumonía infantil en Ecuador. Rev Pediatr Ecuat. 2021;38(3):210-218.
[7] Von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C, et al. Effects of PCV13 in South Africa. N Engl J Med. 2014;371(20):1889-1899.
[8] Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of PCV13 against invasive pneumococcal disease among US children. Clin Infect Dis. 2014;59(9):1177-1185.
